Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Loerenskog – page 106

1 469 clinical trials in Loerenskog, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Loerenskog at a glance
1 469
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 469 trials in Loerenskog

Open in trial search

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AC102
  • Sponsor:AudioCure Pharma GmbH

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Glioblastoma

Not recruiting

Study on Bevacizumab for Patients with Newly Diagnosed IDH Wild-Type, MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Loerenskog

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on pulmonary diseases including trials for new treatments in idiopathic pulmonary fibrosis and COPD. Studies evaluating innovative therapies for chronic wet cough in children and investigating respiratory complications in systemic autoimmune conditions.

  • Pulmonary Fibrosis Treatment
  • COPD Management
  • Pediatric Respiratory Care

Advanced clinical research examining both medication efficacy and symptom management approaches.

02 Gastrointestinal Disorders

Comprehensive studies on inflammatory bowel diseases, including trials for Ulcerative Colitis and Crohn's Disease. Research extends to liver conditions like Primary Sclerosing Cholangitis and colorectal cancer treatments.

  • IBD Treatments
  • Liver Disease Therapies
  • Colorectal Cancer Diagnostics

Innovative approaches focusing on long-term disease management and diagnostic advancement.

03 Oncology Research

Groundbreaking trials in hematological malignancies and solid tumors, including studies on chronic lymphocytic leukemia, lung cancer, and mesothelioma. Focus on combination therapies and targeted treatments.

  • Blood Cancer Treatments
  • Lung Cancer Therapy
  • Novel Cancer Medications

Advanced therapeutic approaches combining immunotherapy with conventional treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.